Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: Double blind, randomized Clinical trial of efficacy, immunogenicity, and safety

Clinical Infectious Diseases

Volumn 52, Issue 1, 2011, Pages 128-137

  Madhi, Shabir A ^a   Maskew, Mhairi ^a   Koen, Anthonet ^a   Kuwanda, Locadiah ^a   Besselaar, Terry G ^b   Naidoo, Dhamari ^b   Cohen, Cheryl ^b,c   Valette, Martine ^d   Cutland, Clare L ^a   Sanne, Ian ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LAMIVUDINE; NEVIRAPINE; PLACEBO; SODIUM CHLORIDE; STAVUDINE; TRIVALENT INACTIVATED INFLUENZA VACCINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIGOR; SEROCONVERSION; SOUTH AFRICA; THROAT CULTURE;

EID: 79951638732     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq004     Document Type: Article

References (30)

1. Prevention control of influenza. MMWR Morb Mortal Wkly Rep 1988;37(23):364, 369-373.
2. Radwan HM, Cheeseman SH, Lai KK, Ellison RT III. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season 2000;31(2):604-606.
3. Nabeshima S, Ariyama I, Chong Y, et al. Influenza in three patients with human immunodeficiency virus infection 2000;39(7):592-597.
4. Nelson KE, Clements ML, Miotti P, Cohn S, Polk BF. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines 1988;109(5):383-388.
5. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989;262(6):779-783. (Pubitemid 19189001)
6. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA determinants of antibody response. Clin Infect Dis 1999;28(3):541-547. (Pubitemid 29242531)
7. Benne CA, Kroon FP, Harmsen M, Tavares L, Kraaijeveld CA, De Jong JC. Comparison of neutralizing hemagglutination-inhibiting antibody responses to influenza A virus vaccination of human immunodeficiency virus-infected individuals. Clin Diagn Lab Immunol 1998;5(1):114-117. (Pubitemid 28062957)
8. Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review meta-analysis. HIV Med 2008;9(1):57-61.
9. Atashili J, Kalilani L, Adimora AA. Efficacy clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis 2006;6:138.
10. Department of Health. National antiretroviral treatment guidelines, First edition. 2004.
11. World Health Organisation. Recommended composition of influenza virus vaccines for use in the 2008 influenza season. eekly Epidemiological Rec 2007;40:551-556.
12. National Institute for Communicable Diseases. http://www.nicd.ac.za. Accessed 14 April 2009.
13. EMEA. Note for guidance on harmonisation of requirements for influenza vaccines. Committe for proprietary medicinal products (CPMP) EMEA - 12 Mars 1997-CPMP/BWP/214/96.
14. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial 1999;131(6):430-433.
15. Yamanaka H, Teruya K, Tanaka M, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;39(2):167-173. (Pubitemid 40741114)
16. Ranieri R, Veronelli A, Santambrogio C, Pontiroli AE. Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients. AIDS Res Hum Retroviruses 2005;21(5):407-409. (Pubitemid 40800457)
17. NICD. Respiratory virus suveillance, South Africa, 2008. Commun Dis Surveill Bull 7(1); 6-7. www.nicd.ac.za. Accessed 10 October 2009.
18. Neuzil KM, Coffey CS, Mitchel EF Jr., Griffin MR. Cardiopulmonary hospitalizations during influenza season in adults adolescents with advanced HIV infection. J Acquir Immune Defic Syndr 2003;34(3):304-307. (Pubitemid 37377365)
19. Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K. Randomized, double-blind comparative trial of subunit virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009;48(10):1402-1412.
20. Tasker SA, O'Brien WA, Treanor JJ, et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine 1998;16(9-10): 1039-1042. (Pubitemid 28276020)
21. Gunthard HF, Wong JK, Spina CA, et al. Effect of influenza vaccination on viral replication immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000;181(2):522-531. (Pubitemid 30131819)
22. Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, Saah AJ. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study 1996;174(6):1332-1336.
23. Keller M, Deveikis A, Cutillar-Garcia M, et al. Pneumococcal influenza immunization and human immunodeficiency virus load in children. Pediatr Infect Dis J 2000;19(7):613-618. (Pubitemid 30469767)
24. Sullivan PS, Hanson DL, Dworkin MS, Jones JL, Ward JW. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 2000;14(17):2781-2785. (Pubitemid 32118731)
25. Hannoun C, Megas F, Piercy J. Immunogenicity protective efficacy of influenza vaccination. Virus Res 2004;103(1-2): 133-138. (Pubitemid 38649072)
26. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004; (3): CD001269.
27. Beyer WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic field studies. Arch Intern Med 1999;159(2):182-188. (Pubitemid 29055107)
28. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: doubleblind, randomised placebo controlled trial. Lancet 2000;355(9221):2106-2111. (Pubitemid 30364659)
29. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008;198(7):962-970.
30. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004;10(8):811-813. (Pubitemid 39070852)